Enspryng Prices, Coupons, Copay Cards & Patient Assistance
Enspryng (satralizumab) is a member of the interleukin inhibitors drug class and is commonly used for Neuromyelitis Optica Spectrum Disorder.
The cost for Enspryng (120 mg/mL) subcutaneous solution is around $18,896 for a supply of 1 milliliter(s), depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Enspryng prices
Subcutaneous Solution
120 mg/mL
Enspryng subcutaneous solution
from $18,896.02
for 1 milliliter(s)
| Quantity | Per unit | Price |
|---|---|---|
| 1 milliliter | $18,896.02 | $18,896.02 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Enspryng Coupons, Copay Cards and Rebates
Enspryng offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Enspryng Co-pay Program
Eligible commercially insured patients may pay$0 per prescription; maximum savings of $20,000 per calendar year.
- Applies to:
- Enspryng
- Number of uses:
- Per prescription per calendar year
Form more information phone: 800-636-0373 or Visit website
Enspryng Co-pay Program Reimbursement Request Form
Eligible commercially insured patients may apply for reimbursement after paying in full for their prescription.
- Applies to:
- Enspryng
- Number of uses:
- One rebate per prescription fill
Form more information phone: 800-636-0373 or Visit website
Patient Assistance & Copay Programs for Enspryng
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Enspryng (satralizumab-mwge) Injection; Subcutaneous
More information please phone: 866-316-7263 Visit Website
Provider: Good Days Program
Eligibility requirements:- Must have insurance
- At or below 500% of FPL
- FDA-approved diagnosis
- The patient must also be a US resident with a Social Security Number.
- Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly.
- Enspryng (satralizumab-mwge) Injection; Subcutaneous
More information please phone: 877-968-7233 Visit Website
Provider: Genentech Patient Foundation
Eligibility requirements:- Uninsured or Underinsured with no prescription coverage for needed medication
- Based on FPL
- Medically appropriate condition/diagnosis
- Must be treated by US licensed healthcare provider
- The Genentech Access to Care Foundation is now the Genentech Patient Foundation. Eligibility determined on a case-by-case basis. Call for most recent medications as the list is subject to change. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
- Enspryng (satralizumab-mwge) Injection; Subcutaneous
More information please phone: 888-941-3331 or 866-422-2377 Visit Website
Provider: Genentech Access Solutions: Enspryng
Eligibility requirements:- Determined case by case
- Based on FPL
- FDA-approved diagnosis
- Must be residing in the US or US territory
- Eligibility determined on a case-by-case basis. Contact program for details. Co-payment assistance, and patient assistance programs are available for eligible patients.
- Enspryng (satralizumab-mwge) Injection; Subcutaneous
More information please phone: 844-677-7964 or 866-422-2377 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Uplizna
Uplizna is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) or ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Inebilizumab
Inebilizumab is used to treat adults with NMOSD (neuromyelitis optica spectrum disorder) who are ...
Ravulizumab
Ravulizumab-cwvz is used to treat myasthenia gravis (gMG), hemolytic uremic syndrome (aHUS) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
More about Enspryng (satralizumab)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
